Visión generalGráficoNoticiasTraderScreen

JTC PLC/  JE00BF4X3P53  /

Cboe Europe CXE
12/11/2024  17:29:54 Diferencia -22.50 Volumen Bid17:30:00 Ask17:30:00 Máximo del día Price Change Band
968.50GBX -2.27% 17,306
Volumen de negocios(GBP): 168,940.9000		 -Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 990.00 968.50
GlobeNewswire 27/08 Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire 27/08 COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire 22/08 Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
GlobeNewswire 21/08 Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual...
GlobeNewswire 20/08 Juventus Football Club Announces Fortinet as Its Official Cybersecurity Partner
GlobeNewswire 20/08 AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Amp...
GlobeNewswire 19/08 Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiat...
GlobeNewswire 19/08 Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 16/08 AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 14/08 Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corpora...
GlobeNewswire 14/08 GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 14/08 Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire 13/08 AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Confere...
GlobeNewswire 13/08 Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 13/08 COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
GlobeNewswire 13/08 Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near...
GlobeNewswire 12/08 Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
GlobeNewswire 08/08 Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
GlobeNewswire 07/08 Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2...
GlobeNewswire 07/08 Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.
GlobeNewswire 02/08 Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
GlobeNewswire 31/07 Palisade Bio Participates in Virtual Investor “What this Means” Segment
GlobeNewswire 30/07 Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
GlobeNewswire 29/07 AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GlobeNewswire 29/07 Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactiv...